Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01.
about
Development of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemiaGenome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemiaLong-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000).Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia.Immunologic minimal residual disease detection in acute lymphoblastic leukemia: a comparative approach to molecular testingNew markers for minimal residual disease detection in acute lymphoblastic leukemia.Asparaginase-associated myelosuppression and effects on dosing of other chemotherapeutic agents in childhood acute lymphoblastic leukemia.Proposal for the standardization of flow cytometry protocols to detect minimal residual disease in acute lymphoblastic leukemiaPharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children's Oncology GroupDeep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia.Measurements of treatment response in childhood acute leukemia.Determination of ETV6-RUNX1 genomic breakpoint by next-generation sequencing.Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer InstitutClinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.Minimal Residual Disease Evaluation in Childhood Acute Lymphoblastic Leukemia: A Clinical Evidence Review.Progress of minimal residual disease studies in childhood acute leukemia.Minimal residual disease in acute lymphoblastic leukemiaThe low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium.Analysis of Patterns of Gene Expression Variation within and between Ethnic Populations in Pediatric B-ALLDetermining the repertoire of IGH gene rearrangements to develop molecular markers for minimal residual disease in B-lineage acute lymphoblastic leukemia.A simplified minimal residual disease polymerase chain reaction method at early treatment points can stratify children with acute lymphoblastic leukemia into good and poor outcome groupsStatus of minimal residual disease testing in childhood haematological malignanciesRole of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia.Pharmacogenomics of pediatric acute lymphoblastic leukemia.Should minimal residual disease monitoring in acute lymphoblastic leukemia be standard of care?Detection of minimal residual disease in pediatric acute lymphoblastic leukemia.Minimal residual disease in acute lymphoblastic leukemia: optimal methods and clinical relevance, pitfalls and recent approaches.Minimal Residual Disease and Childhood Leukemia: Standard of Care Recommendations From the Pediatric Oncology Group of Ontario MRD Working Group.Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia: A Meta-analysis.The long-term impact of in vitro drug sensitivity on risk stratification and treatment outcome in acute lymphoblastic leukemia of childhood (CoALL 06-97).Minimal residual disease in peripheral blood at day 15 identifies a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with superior prognosis.Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia.The effect of peritransplant minimal residual disease in adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation.Screening for residual disease in pediatric burkitt lymphoma using consensus primer pools.Increased expression of costimulatory molecules CD86 and sCTLA-4 in patients with acute lymphoblastic leukemia.Next-generation sequencing-based detection of circulating tumour DNA After allogeneic stem cell transplantation for lymphoma.High proportion of CD34+/CD38-cells is positively correlated with poor prognosis in newly diagnosed childhood acute lymphoblastic leukemia.Molecular Analysis of Gene Rearrangements and Mutations in Acute Leukemias and Myeloid Neoplasms.Minimal residual disease assessment in childhood acute lymphoblastic leukaemia: a Swedish multi-centre study comparing real-time polymerase chain reaction and multicolour flow cytometry.Sequential monitoring of minimal residual disease in acute lymphoblastic leukemia: 7-year experience in a pediatric hematology/oncology unit.
P2860
Q26825970-5F556BA6-C35C-45B5-BF33-A3A2DA186B55Q28943308-B00EA194-4992-47A0-8E0C-7CD0B97CA775Q33645760-96D9F7B8-2202-4CBF-8BCD-43446B24E538Q33931882-68063ED3-1F61-4E8A-99E8-27655A18B734Q34425875-FAD3DDB5-57A8-449E-B389-2E4F3DB096C2Q35067391-5A4AE6AA-C97A-4EA9-8EE9-21EAB40D0776Q36105259-A217AFA7-6AD6-424F-ABFB-1BD037F55E9FQ36371093-0944AD70-D51F-42E9-8178-038CAE1A4EC8Q36491833-49CC97F4-1374-4098-B796-ECFC1C7E590DQ36509641-B79CD01A-C1F6-4ECD-B082-C4AE276102F5Q36513773-294AC15C-DD2A-4060-A380-E59E1162AB3BQ36528412-263A6D20-BEEA-4E86-92BA-B8B0748E2C07Q36678136-3B7951DB-0649-45BC-92BB-BEC52036CBFFQ36713493-34AC37AB-67B2-4E4B-BC58-9904ADDA7DF6Q36731636-74353F14-ED19-4EA7-AD52-CB24F4063D7CQ36981845-CAE966FE-54CA-4FAB-9E1F-FF3A8797D21DQ37077352-F0F0642A-1C2C-42FE-8BBC-A124F6058730Q37078647-26BF39A6-F662-4715-8FCA-875ACBBEC332Q37146303-92282D47-C740-40E5-B871-A454C01AA38AQ37164456-6293D695-30A9-4A17-B61E-F639867E218FQ37207757-24297FAB-5FFD-47F4-8EE5-863ADD0E8D07Q37246360-595EA9FC-0569-4019-B8A2-6B3B936081E9Q37389544-5E2E3123-9E86-4251-BD35-EB4980A762E6Q37739432-0F85992B-3203-4057-B674-011D7A3DC688Q37989006-2C0FD665-2C37-4714-B205-93A4CB608DA9Q38113738-23302D4B-4C50-41CB-9C9C-2CA5D138C363Q38257363-351A3552-67AA-44AD-8041-CE7AB8DF352AQ38749564-80B431BC-A7FC-4B8D-8758-1BA86D95447EQ38792016-39AD7C21-6085-419A-9236-F2C5AF5C90FEQ39205653-2FE49C8D-7D55-47C4-9E75-8A6EE9376976Q39646177-2FDA8205-2A83-43CE-A823-3BFA9DFB5606Q40910460-777B6DEF-D020-4F06-80D4-802B805BE072Q41688221-8F83A736-4B9C-413E-9D4B-CB0057408CA8Q42139949-F1BD0556-4519-4D8E-BB80-6EC54A62C2C7Q46624489-7EC25AC1-0CB5-486E-8332-CF186AE61823Q47603352-FEE636D7-2888-4C5F-BE28-47FF0DE6A0C4Q50962385-30C35E65-BAE1-45A5-BF6D-B71C928C12EDQ51200437-40C07127-C39A-4497-9284-B3A352A4AE0AQ54391883-0C13A988-6532-4F0E-974B-BB03D8FF1EA7Q54434736-C24F1C64-7462-496C-B541-67DB9FCD7045
P2860
Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Quantitative analysis of minim ...... ALL Consortium Protocol 95-01.
@ast
Quantitative analysis of minim ...... ALL Consortium Protocol 95-01.
@en
type
label
Quantitative analysis of minim ...... ALL Consortium Protocol 95-01.
@ast
Quantitative analysis of minim ...... ALL Consortium Protocol 95-01.
@en
prefLabel
Quantitative analysis of minim ...... ALL Consortium Protocol 95-01.
@ast
Quantitative analysis of minim ...... ALL Consortium Protocol 95-01.
@en
P2093
P2860
P1433
P1476
Quantitative analysis of minim ...... ALL Consortium Protocol 95-01
@en
P2093
Dana-Farber Cancer Institute ALL Consortium
Donna Neuberg
Hongjun Wang
Jianbiao Zhou
John G Gribben
Kathryn D McBride
Lewis B Silverman
Meredith A Goldwasser
Stephen E Sallan
P2860
P304
P356
10.1182/BLOOD-2006-09-045369
P407
P577
2007-05-07T00:00:00Z